"People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of ...
Eli Lilly just scored a major win with its Phase 3 BRAVE-AA-PEDS study. The trial confirmed baricitinib's effectiveness in ...
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
The Maryland Senate voted to allow a state board to extend its mandate for lowering prescription drug costs to all residents.
Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...
Uncertainty around President Donald Trump’s tariff policies have sent the major averages on a roller-coaster ride and spurred ...
Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in ...
Novo Nordisk ( NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...
Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Novo Nordisk (NVO – Research Report) and Veeva Systems (VEEV ...
NewsNation on MSN12d
AbbVie enters into almost $2B contract with Gubra for obsesity drugBloomberg reports the obesity drug market is expected to reach as much as $130 billion in annual sales by 2030.
The weight-loss drug can cost patients more than $1,000 a month if they do not have health insurance coverage.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback